Injuries Linked to Ozempic – You May Be Entitled to Compensation
Have you or a loved one experienced severe gastrointestinal issues after using Ozempic or other GLP-1 receptor agonists?
Recent legal actions highlight allegations of significant health risks associated with Ozempic, an injectable prescription medication manufactured by Novo Nordisk for type 2 diabetes and weight management. Users of this drug have reported serious complications, including intestinal obstruction, delayed gastric emptying, and other debilitating gastrointestinal conditions.
It has been alleged that Novo Nordisk failed to warn users of Ozempic about these severe risks despite being aware of the potential dangers from clinical studies and medical literature. Instead, it is alleged that the company aggressively marketed the drug, emphasizing its benefits while minimizing or omitting critical safety information.
Commonly Reported Injuries:
- Intestinal obstruction
- Severe nausea and vomiting
- Gastrointestinal paralysis
- Persistent abdominal pain
- Long-term medical complications
Why Act Now?
If you or a loved one has suffered from similar health issues after taking Ozempic, you may be entitled to compensation for:
- Medical expenses
- Pain and suffering
- Lost wages
- Reduced quality of life
Sauder Schelkopf is actively investigating claims related to Ozempic injuries. We are committed to holding pharmaceutical companies accountable and ensuring those injured receive the justice they deserve.
Experience Matters
Sauder Schelkopf has a nationally recognized litigation practice. The firm currently serves as court-appointed lead counsel in courts across the country. The attorneys at Sauder Schelkopf have recovered over $1 billion on behalf of their clients and class members. Our firm was recognized by the Legal Intelligencer’s 2022 Professional Excellence Awards. The Legal Intelligencer’s Professional Excellence Awards honor Pennsylvania law firms and attorneys who have made a significant, positive impact on the legal profession. Our firm was named in the Litigation Departments of the Year (Specialty Area category; runner-up), an award that honors the best litigation practice in a small or mid-sized firm in Pennsylvania. This recognition was based on the firm’s 2021 litigation work and its important ongoing cases. LawDragon has recognized our attorneys in its list of the “500 Leading Plaintiff Consumer Lawyers” for 2022. This list notes: “From the opioid epidemic to toxic substances and defective products, truck accidents to wildfires and sexual abuse, these are the lawyers who stand on the front line in individual lawsuits and class actions seeking justice.” Mr. Schelkopf was named to Pennsylvania’s Best Lawyers® 2022 for Class Actions/Mass Tort Litigation. The American Lawyer named Mr. Sauder to its 2021 Northeast Trailblazers. The honor recognizes 60 lawyers who are “truly agents of change.” It “recognizes professionals in the Northeast who have moved the needle in the legal industry.” The Legal Intelligencer named Mr. Sauder and Mr. Schelkopf in its 2020 Pennsylvania Trailblazers list recognizing 31 lawyers who “have taken extra measures to contribute to positive outcomes . . . and who are truly agents of change.” The Legal highlighted the firm’s innovative work on advocacy as class counsel in large institutional sex abuse cover-ups, women’s, and children’s rights. Our attorneys have also consistently been recognized by their peers being named to Pennsylvania SuperLawyer, a distinction held by the top 5% of attorneys in Pennsylvania. The National Trial Lawyers Association has also selected our attorneys as the Top 100 Trial Lawyers in Pennsylvania.
We Want to Hear from You
If you or a loved one experienced severe gastrointestinal issues after using Ozempic or other GLP-1 receptor agonists, contact the attorneys at Sauder Schelkopf by filling out the form on this page.